Michael Ulz
Stock Analyst at Baird
(4.16)
# 434
Out of 4,873 analysts
115
Total ratings
53.23%
Success rate
13.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $54 → $42 | $4.65 | +803.23% | 6 | May 13, 2025 | |
| SLN Silence Therapeutics | Maintains: Overweight | $45 → $25 | $6.06 | +312.54% | 12 | May 9, 2025 | |
| VKTX Viking Therapeutics | Maintains: Overweight | $105 → $102 | $26.95 | +278.48% | 3 | Apr 24, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $284 → $268 | $325.00 | -17.54% | 10 | Apr 11, 2025 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $40 → $20 | $3.19 | +527.94% | 2 | Apr 1, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $30 → $22 | $1.77 | +1,142.94% | 6 | Apr 1, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Overweight | $29 | $15.76 | +84.01% | 1 | Mar 10, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Underweight | $11 → $7 | $5.13 | +36.45% | 7 | Mar 5, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $24 → $20 | $1.88 | +963.83% | 4 | Feb 28, 2025 | |
| THRD Third Harmonic Bio | Downgrades: Equal-Weight | $20 → $5 | $5.43 | -7.92% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $10 | $1.70 | +488.24% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $96 | $53.92 | +78.04% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $52 | $10.63 | +389.18% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $110 → $115 | $128.26 | -10.34% | 9 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $57 | $51.11 | +11.52% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $36 → $27 | $15.95 | +69.33% | 4 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $1.17 | +498.29% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $45 → $48 | $39.65 | +21.06% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $10.49 | +157.39% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $2.00 | +900.00% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $2.77 | +1,524.55% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $10 | $0.67 | +1,401.50% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $2.37 | +26.58% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $5.27 | +469.80% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $30 | $1.18 | +2,442.37% | 3 | Mar 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $10.09 | +345.99% | 1 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $20 | $0.34 | +5,754.80% | 2 | May 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $37.16 | +115.29% | 3 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $5.71 | +162.70% | 3 | Jul 12, 2017 |
Karyopharm Therapeutics
May 13, 2025
Maintains: Outperform
Price Target: $54 → $42
Current: $4.65
Upside: +803.23%
Silence Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $45 → $25
Current: $6.06
Upside: +312.54%
Viking Therapeutics
Apr 24, 2025
Maintains: Overweight
Price Target: $105 → $102
Current: $26.95
Upside: +278.48%
Alnylam Pharmaceuticals
Apr 11, 2025
Maintains: Equal-Weight
Price Target: $284 → $268
Current: $325.00
Upside: -17.54%
Kyverna Therapeutics
Apr 1, 2025
Maintains: Overweight
Price Target: $40 → $20
Current: $3.19
Upside: +527.94%
Cabaletta Bio
Apr 1, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $1.77
Upside: +1,142.94%
Aardvark Therapeutics
Mar 10, 2025
Initiates: Overweight
Price Target: $29
Current: $15.76
Upside: +84.01%
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Underweight
Price Target: $11 → $7
Current: $5.13
Upside: +36.45%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $1.88
Upside: +963.83%
Third Harmonic Bio
Feb 12, 2025
Downgrades: Equal-Weight
Price Target: $20 → $5
Current: $5.43
Upside: -7.92%
Feb 3, 2025
Maintains: Overweight
Price Target: $18 → $10
Current: $1.70
Upside: +488.24%
Jan 28, 2025
Maintains: Overweight
Price Target: $46 → $96
Current: $53.92
Upside: +78.04%
Aug 14, 2024
Maintains: Overweight
Price Target: $48 → $52
Current: $10.63
Upside: +389.18%
Jul 12, 2024
Maintains: Equal-Weight
Price Target: $110 → $115
Current: $128.26
Upside: -10.34%
Jun 18, 2024
Maintains: Overweight
Price Target: $53 → $57
Current: $51.11
Upside: +11.52%
May 13, 2024
Maintains: Equal-Weight
Price Target: $36 → $27
Current: $15.95
Upside: +69.33%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $1.17
Upside: +498.29%
Nov 3, 2023
Maintains: Equal-Weight
Price Target: $45 → $48
Current: $39.65
Upside: +21.06%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $10.49
Upside: +157.39%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $2.00
Upside: +900.00%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $2.77
Upside: +1,524.55%
Jan 27, 2023
Maintains: Overweight
Price Target: $20 → $10
Current: $0.67
Upside: +1,401.50%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $2.37
Upside: +26.58%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $5.27
Upside: +469.80%
Mar 30, 2022
Maintains: Equal-Weight
Price Target: $25 → $30
Current: $1.18
Upside: +2,442.37%
Oct 8, 2020
Initiates: Outperform
Price Target: $45
Current: $10.09
Upside: +345.99%
May 28, 2020
Maintains: Outperform
Price Target: $12 → $20
Current: $0.34
Upside: +5,754.80%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $37.16
Upside: +115.29%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $5.71
Upside: +162.70%